Erythroid progenitors from patients with low-risk myelodysplastic syndromes are dependent on the surrounding micro environment for their survival

被引:1
|
作者
Folkerts, Hendrik [1 ]
Hazenberg, Carin L. E. [1 ]
Houwerzijl, Ewout J. [2 ]
van den Heuvel, Fiona A. J. [1 ,3 ]
Mulder, Andre B. [3 ]
van der Want, Johannes J. L. [4 ,5 ]
Vellenga, Edo [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9700 RB Groningen, Netherlands
[5] Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, N-7034 Trondheim, Norway
关键词
BONE-MARROW; ENHANCED AUTOPHAGY; STEM-CELL; MEGAKARYOCYTES; PRECURSORS; HEMATON;
D O I
10.1016/j.exphem.2014.11.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To investigate whether the type of programmed cell death of myelodysplastic erythroid cells depends on their cellular context, we performed studies on cells from patients with low-risk myelodysplastic syndromes. We compared erythroid cells (and their precursor cells) from the mononuclear cell fraction with those from the hematon fraction, which are compacted complexes of hematopoietic cells surrounded by their own micro-environment. In directly fixed materials, erythroblasts exhibited signs of autophagy with limited apoptosis (<3%) based on ultrastructural characteristics and immunogold labeling for activated caspase-3. After 24 h in culture, myelodysplastic erythroblasts exhibited a significant increase in apoptosis (22 +/- 7% vs. 3 +/- 2%, p = 0.001). In contrast, the myelodysplastic erythroblasts from the hematon fraction did not exhibit an increased tendency toward apoptosis after culture (7 +/- 3.3% vs. 1.8 +/- 2.3%), which was in line with results for normal bone marrow cells. The same dependency on the micro-environment was noted for immature erythroid progenitor cells. Myelodysplastic hematons exhibited distinct numbers of erythroid burst-forming units in association with an extensive network of stromal cells, whereas small numbers of erythroid burst-forming units were generated from the myelodysplastic mononuclear cells compared with normal mononuclear cells (10.2 +/- 9 vs. 162 +/- 125, p < 0.001). Co-culture of erythroid myelodysplastic cells in the presence of growth factors (vascular endothelial growth factor, leukemia inhibitory factor) or on the MS-5 stromal layer did not restore the expansion of erythroid precursor cells. These data indicate that surviving myelodysplastic erythroid progenitors become more vulnerable to programmed cell death when they are detached from their own micro-environment. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [31] Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
    Patel, Bhumika
    Saygin, Caner
    Przychodzen, Bartlomiej P.
    Kuzmanovic, Teodora
    Hirsch, Cassandra M.
    Clemente, Michael J.
    Thota, Swapna
    Nazha, Aziz
    Mikkael, Sekeres A.
    Maciejewski, Jaroslaw P.
    Carraway, Hetty E.
    BLOOD, 2016, 128 (22)
  • [32] Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept
    Fattizzo, Bruno
    Marchetti, Alfredo
    Zaninoni, Anna
    Lionetti, Marta
    Riva, Marta
    Rizzo, Lorenzo
    Pettine, Loredana
    Galli, Nicole
    Mazzon, Federico
    Fermo, Elisa
    Maeda, Akihiro
    Marella, Alessio
    Da Via, Matteo Claudio
    Passamonti, Francesco
    Bolli, Niccolo
    Barcellini, Wilma
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : E345 - E348
  • [33] Clinical responses to alemtuzumab in six patients with low-risk myelodysplastic syndromes and aplastic anemia
    Neukirchen, J.
    Strupp, C.
    Kuendgen, A.
    Tsamaloukas, A.
    Haas, R.
    Germing, U.
    ONKOLOGIE, 2012, 35 : 148 - 149
  • [34] High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes
    Riabov, Vladimir
    Mossner, Maximilian
    Stoehr, Alexandra
    Jann, Johann-Christoph
    Streuer, Alexander
    Schmitt, Nanni
    Knaflic, Antje
    Nowak, Verena
    Weimer, Nadine
    Oblaender, Julia
    Palme, Iris
    Schumann, Christiane
    Baldus, Claudia D.
    Schulze, Torsten J.
    Wuchter, Patrick
    Roehl, Henning
    Jawhar, Ahmed
    Weiss, Christel
    Boch, Tobias
    Metzgeroth, Georgia
    Neumann, Martin
    Hofmann, Wolf-Karsten
    Nolte, Florian
    Nowak, Daniel
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (05) : 879 - 891
  • [35] Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
    Hartmann, Julia
    Braulke, Friederike
    Sinzig, Ursula
    Wulf, Gerald
    Maas, Jens Holger
    Konietschke, Frank
    Haase, Detlef
    LEUKEMIA RESEARCH, 2013, 37 (03) : 327 - 332
  • [36] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 879 - 888
  • [37] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
    Fenaux, P
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
  • [38] Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes
    Tamburini, J.
    Elie, C.
    Park, S.
    Beyne-Rauzy, O.
    Gardembas, M.
    Berthou, C.
    Mahe, B.
    Sanhes, L.
    Stamatoullas, A.
    Vey, N.
    Aouba, A.
    Slama, B.
    Quesnel, B.
    Vekhoff, A.
    Sotto, J. J.
    Vassilief, D.
    Al-Nawakil, C.
    Fenaux, P.
    Dreyfus, F.
    Bouscary, D.
    LEUKEMIA RESEARCH, 2009, 33 (04) : 547 - 550
  • [39] Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
    Meunier, Mathieu
    Ancelet, Sarah
    Lefebvre, Christine
    Arnaud, Josiane
    Garrel, Catherine
    Pezet, Mylene
    Wang, Yan
    Faure, Patrice
    Szymanski, Gautier
    Duployez, Nicolas
    Preudhomme, Claude
    Biard, Denis
    Polack, Benoit
    Cahn, Jean-Yves
    Moulis, Jean Marc
    Park, Sophie
    ONCOTARGET, 2017, 8 (62): : 105510 - 105524
  • [40] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Maciejewski, Jaroslaw R.
    Golshayan, Ali-Reza
    Kalaycio, Matt E.
    Kaftan, Michael W.
    CANCER, 2007, 109 (06) : 1125 - 1132